Carbogen Amcis Announces Plan to Restructure

Swiss Carbogen Amcis, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has advised its employees and the authorities today of its plans for restructuring the Swiss company's operations in Bubendorf (BL), Aarau (AG) and Hunzenschwil (Neuland, AG).

The company finds itself forced to take this step on the grounds of the inadequate profitability brought about by the strong Swiss franc and the delayed effects of the financial crisis. The company currently has approximately 350 employees in Switzerland.

The planned restructuring of the leading pharmaceutical services company will allow the Aarau site to focus more strongly on development and the Hunzenschwil (Neuland) site on the pilot production of early phase projects.

Large-volume production and the manufacturing of highly active agents will continue at the Bubendorf site.

This concentration of the areas of responsibility will mean that approximately 60 persons will need to be made redundant. Carbogen Amcis is strengthening man power in the Hunzenschwil (Neuland) site to innovatively meet customer demand further on. As far as possible, employees will be offered equivalent positions in Switzerland.

"During the transition we will direct our focus, as we would in any case, towards attending to customer demand and providing our customers with consistently high service," said Jay R. Vyas, managing director of the Dishman Group, owner of Carbogen Amcis.

"The restructuring allows Carbogen Amcis to be prepared for the future as a sustainably successful organization. The restructured company will have potential for growth and the ability to adapt itself to a changing market situation."

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.